Feasibility of affibody-based bioorthogonal chemistry-mediated radionuclide pretargeting

Journal of Nuclear Medicine

Volumn 57, Issue 3, 2016, Pages 431-436

  Altai, Mohamed ^a   Perols, Anna ^b   Tsourma, Maria ^a   Mitran, Bogdan ^a   Honarvar, Hadis ^a   Robillard, Marc ^c   Rossin, Raffaella ^c   Ten Hoeve, Wolter ^d   Lubberink, Mark ^a   Orlova, Anna ^a   Karlström, Amelie Eriksson ^b   Tolmachev, Vladimir ^a  

^a UPPSALA UNIVERSITY   (Sweden)

^b ROYAL INSTITUTE OF TECHNOLOGY   (Sweden)

^c Tagworks Pharmaceuticals   (Netherlands)

^d Syncom BV   (Netherlands)

Author keywords

Affibody; Engineered scaffold protein; Radionuclide pretargeting; Radionuclide therapy; Tetrazine; Trans cyclooctene

Indexed keywords

AFFIBODY; EPIDERMAL GROWTH FACTOR RECEPTOR 2; INDIUM 111; LUTETIUM 177; MONOCLONAL ANTIBODY; SCAFFOLD PROTEIN; TETRAZINE DERIVATIVE; TETRAZINE IN 111; TETRAZINE LU 177; TRACER; UNCLASSIFIED DRUG; Z 2395 TRANS CYCLOOCTENE I 125; ERBB2 PROTEIN, HUMAN; RADIOISOTOPE; RADIOPHARMACEUTICAL AGENT;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BINDING AFFINITY; BIOORTHOGONAL CHEMISTRY; BREAST CANCER CELL LINE; CHEMISTRY; CONJUGATION; CONTROLLED STUDY; FEMALE; IN VIVO STUDY; INTERNALIZATION; ISOTOPE LABELING; KIDNEY; MOUSE; NONHUMAN; ORGAN DISTRIBUTION; OVARIAN CANCER CELL LINE; PRIORITY JOURNAL; RADIONUCLIDE PRETARGETING; SCINTISCANNING; TUMOR XENOGRAFT; ANIMAL; BAGG ALBINO MOUSE; DRUG DELIVERY SYSTEM; DRUG SCREENING; FEASIBILITY STUDY; HUMAN; KIDNEY NEOPLASMS; NEOPLASMS; NUDE MOUSE; PROCEDURES; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; TUMOR CELL LINE;

ANIMALS; CELL LINE, TUMOR; DRUG DELIVERY SYSTEMS; FEASIBILITY STUDIES; FEMALE; HUMANS; KIDNEY NEOPLASMS; MICE; MICE, INBRED BALB C; MICE, NUDE; NEOPLASMS; RADIOISOTOPES; RADIOPHARMACEUTICALS; RECEPTOR, ERBB-2; TOMOGRAPHY, EMISSION-COMPUTED, SINGLE-PHOTON; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84960118391     PISSN: 01615505     EISSN: 2159662X     Source Type: Journal    
DOI: 10.2967/jnumed.115.162248     Document Type: Article

References (30)

1. Tolmachev V, Stone-Elander S, Orlova A. Radiolabelled receptor-tyrosine-kinase targeting drugs for patient stratification and monitoring of therapy response: Prospects and pitfalls. Lancet Oncol. 2010;11: 992-1000.
2. Pouget JP, Navarro-Teulon I, Bardiès M, et al. Clinical radioimmunotherapy: The role of radiobiology. Nat Rev Clin Oncol. 2011;8: 720-734.
3. Binz HK, Amstutz P, Pluckthun A. Engineering novel binding proteins from nonimmunoglobulin domains. Nat Biotechnol. 2005;23: 1257-1268.
4. Ahlgren S, Tolmachev V. Radionuclide molecular imaging using affibody molecules. Curr Pharm Biotechnol. 2010;11: 581-589.
5. Zahnd C, Kawe M, Stumpp MT, et al. Efficient tumor targeting with high-affinity designed ankyrin repeat proteins: Effects of affinity and molecular size. Cancer Res. 2010;70: 1595-1605.
6. Hackel BJ, Kimura RH, Gambhir SS. Use of 64Cu-labeled fibronectin domain with EGFR-overexpressing tumor xenograft: Molecular imaging. Radiology. 2012; 263: 179-188.
7. Terwisscha van Scheltinga AG, Lub-de Hooge MN, Hinner MJ, et al. In vivo visualization of MET tumor expression and anticalin biodistribution with the MET-specific anticalin 89Zr-PRS-110 PET tracer. J Nucl Med. 2014;55: 665-671.
8. Ackerman SE, Currier NV, Bergen JM, Cochran JR. Cystine-knot peptides: Emerging tools for cancer imaging and therapy. Expert Rev Proteomics. 2014;11: 561-572.
9. Garousi J, Lindbo S, Astrand M, et al. ADAPT, a novel scaffold protein-based probe for radionuclide imaging of molecular targets in disseminated cancer. Cancer Res. 2015;75: 4364-4371.
10. Sörensen J, Sandberg D, Sandström M, et al. First-in-human molecular imaging of HER2 expression in breast cancer metastases using the 111In-ABY-025 affibody molecule. J Nucl Med. 2014;55: 730-735.
11. Fortin MA, Orlova A, Malmström PU, Tolmachev V. Labelling chemistry and characterization of [90Y/177Lu]-DOTA-ZHER2: 342-3 affibody molecule, a candidate agent for locoregional treatment of urinary bladder carcinoma. Int J Mol Med. 2007;19: 285-291.
12. Wållberg H, Orlova A. Slow internalization of anti-HER2 synthetic affibody monomer 111In-DOTA-ZHER2: 342-pep2: Implications for development of labeled tracers. Cancer Biother Radiopharm. 2008;23: 435-442.
13. Tolmachev V, Rosik D, Wållberg H, et al. Imaging of EGFR expression in murine xenografts using site-specifically labelled anti-EGFR 111In-DOTA-Z EGFR: 2377 affibody molecule: Aspect of the injected tracer amount. Eur J Nucl Med Mol Imaging. 2010;37: 613-622.
14. Orlova A, Hofström C, Strand J, et al. [99mTc(CO)3]1-(HE)3-ZIGF1R: 4551, a new affibody conjugate for visualization of insulin-like growth factor-1 receptor expression in malignant tumours. Eur J Nucl Med Mol Imaging. 2013;40: 439-449.
15. Tolmachev V, Mume E, Sjöberg S, Frejd FY, Orlova A. Influence of valency and labelling chemistry on in vivo targeting using radioiodinated HER2-binding affibody molecules. Eur J Nucl Med Mol Imaging. 2009;36: 692-701.
16. Orlova A, Tran TA, Ekblad T, Karlström AE, Tolmachev V. 186Re-maSGS-Z (HER2: 342), a potential affibody conjugate for systemic therapy of HER2- expressing tumours. Eur J Nucl Med Mol Imaging. 2010;37: 260-269.
17. Altai M, Wållberg H, Honarvar H, et al. 188Re-ZHER2: V2, a promising affibodybased targeting agent against HER2-expressing tumors: Preclinical assessment. J Nucl Med. 2014;55: 1842-1848.
18. Tolmachev V. Choice of radionuclides and radiolabeling techniques In: Stigbrand T, Carlsson J, Adams GP, eds. Targeted Radionuclide Tumor Therapy: Biological Aspects. New York, NY: Springer Science 1 Business Media B.V.; 2008: 145-174.
19. van de Watering FC, Rijpkema M, Robillard M, Oyen WJ, Boerman OC. Pretargeted imaging and radioimmunotherapy of cancer using antibodies and bioorthogonal chemistry. Front Med (Lausanne). 2014;1: 44.
20. Hnatowich DJ, Virzi F, Rusckowski M. Investigations of avidin and biotin for imaging applications. J Nucl Med. 1987;28: 1294-1302.
21. Liu G, Mangera K, Liu N, Gupta S, RusckowskiM, Hnatowich DJ. Tumor pretargeting in mice using 99mTc-labeled morpholino, a DNA analog. J Nucl Med. 2002;43: 384-391.
22. Goldenberg DM, Chang CH, Rossi EA. J W, McBride, Sharkey RM. Pretargeted molecular imaging and radioimmunotherapy. Theranostics. 2012;2: 523-540.
23. Rossin R, Verkerk PR, van den Bosch SM, et al. In vivo chemistry for pretargeted tumor imaging in live mice. Angew Chem Int Ed Engl. 2010;49: 3375-3378.
24. Taylor MT, Blackman ML, Dmitrenko O, Fox JM. Design and synthesis of highly reactive dienophiles for the tetrazine-trans-cyclooctene ligation. J Am Chem Soc. 2011;133: 9646-9649.
25. Tolmachev V, Wållberg H, Sandström M, Hansson M, Wennborg A, Orlova A. Optimal specific radioactivity of anti-HER2 affibody molecules enables discrimination between xenografts with high and low HER2 expression levels. Eur J Nucl Med Mol Imaging. 2011;38: 531-539.
26. Altai M, Strand J, Rosik D, et al. Influence of nuclides and chelators on imaging using affibody molecules: Comparative evaluation of recombinant affibody molecules site-specifically labeled with 68Ga and 111In via maleimido derivatives of DOTA and NODAGA. Bioconjug Chem. 2013;24: 1102-1109.
27. Correia JD, Paulo A, Raposinho PD, Santos I. Radiometallated peptides for molecular imaging and targeted therapy. Dalton Trans. 2011;40: 6144-6167.
28. Heppeler A, Froidevaux S, Mäcke HR, et al. Radiometal-labelled macrocyclic chelator-derivatised somatostatin analogue with superb tumour targeting properties and potential for receptor rmediated internal radiotherapy. Chem Eur J. 1999;5: 1974-1981.
29. Valkema R, Pauwels SA, Kvols LK, et al. Long-term follow-up of renal function after peptide receptor radiation therapy with 90Y-DOTA(0),Tyr(3)-octreotide and 177Lu-DOTA(0), Tyr(3)-octreotate. J Nucl Med. 2005;46(suppl 1): 83S-91S.
30. Ilan E, Sandström M, Wassberg C, et al. Dose response of pancreatic neuroendocrine tumors treated with peptide receptor radionuclide therapy using 177Lu- DOTATATE. J Nucl Med. 2015;56: 177-182.